Warning letter
Pharmco Laboratories Inc.: warning letter of Dec 15, 2016
FDA warning letter 486901 · Florida District Office
Key facts
| Reference number | 486901 |
|---|---|
| Company | Pharmco Laboratories Inc. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated/Misbranded |
| Issue date | Dec 15, 2016 |
| Posted date | Jan 31, 2017 |
| Issuing office | Florida District Office |
| Product type | Drugs |
| CFR sections cited | 201.327(e)(1)(ii), 352, 352.10, 211.100(a), 211.160(b), 211.166(a), 201.327, 201.327(d)(2), 201.327(e), 211.165(e), 330.1(c)(2), 333.350(b) and 3 more |
| Inspection city | Titusville |
| Inspection ZIP | 32780 |
| Inspection start date | Nov 9, 2015 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: